Method for detecting concentrations of polymyxin B1 and polymyxin B2 in serum

Abstract

The invention discloses a method for detecting concentrations of polymyxin B1 and polymyxin B2 in serum, and belongs to the technical field of drug detection. The method comprises the following stepsof: taking pretreated serum, separating an object to be detected from a serum matrix by using ultra-high performance liquid chromatography, and calculating the contents of the polymyxin B1 and the polymyxin B2 by using a mass spectrum internal standard quantitative method according to an established calibration curve. The method disclosed by the invention is high in sensitivity, strong in specificity, accurate and simple in pretreatment process; the separation and the detection of the polymyxin B1 and the polymyxin B2 in the serum are completed within 5.0 minutes; the accuracy and precision basically meet the requirements; the method can be used for quantitatively analyzing polymyxin B1 and polymyxin B2 drugs in serum clinically; and a simple and rapid detection method is provided for monitoring the concentrations of the polymyxin B1 and polymyxin B2 drugs clinically.

Description

technical field [0001] The invention belongs to the technical field of drug detection, in particular to a method for detecting drug concentrations of polymyxin B1 and polymyxin B2 in serum. Background technique [0002] Polymyxin B (polymyxin B) is a lipopeptide antibiotic, in which polymyxin B1 (polymyxin B1, PMB1) and polymyxin B2 (polymyxin B2, PMB2) are its two main components. Pseudomonas, Escherichia coli, Klebsiella and Haemophilus and other negative bacteria have inhibitory effect. The product is also sensitive to strains resistant to other antibiotics. However, due to its severe nephrotoxicity and nerve blocking effect, it is only used for short-term rescue of burns complicated with sepsis, or for local spraying for external use. However, current dosing regimens are mostly empirical, and the lack of rapid and accurate methods for the determination of polymyxin B in human body fluids hinders the clinical pharmacological properties of the drug. Therefore, it is nec...

AI Technical Summary

Problems solved by technology

[0003] At present, there are also reports on methods for the quantitative detection of polymyxin B1 and B2. For example, the article "HighPerformance Liquid Chromatography–Mass Spectrometry Assay for Polymyxin B1 and B2 in Human Plasma" reports a method based on liquid chromatography-mass spectrometry for the determination of polymyxin The content of B1 and B2, but this method also has certain defects, for example, the pretreatment of this method uses solid phase extraction method, the sample amount is large, the pretreatment is more complicated and the cost is high; at the same time, the liquid phase method mentioned in the article has a gradient of 12 Minutes, the detection time is too long, and the efficiency is low; moreover, the linear range of this method is 100-2500ng / mL, the linear range is narrow, and it is not suitable for clinical analysis

For another example, the article "Simultaneous quantitation of polymyxin B1, polymyxin B2 and polymyxin B1-1 inhuman plasma and treated human urine using solid phase extraction and liquid chromatography–tandem massspectrometry" reported a method for the determination of polymyxin B1 and B2 based on liquid chromatography-mass spectrometry However, there are also certain defects, such as the cumbersome pretreatment of this method, the need for vortex ultrasonic precipitation of protein, the need for centrifugation and concentration before detection, and the detection time of one needle sample is as long as 20 minutes, which is not suitable for the detection of a large number of clinical samples

Images